Rising Prevalence Of Gastrointestinal Disorders Growth In Fecal Microbiota Transplantation (FMT) Market Driving Market Acceleration in the Fecal Microbiota Transplantation (FMT) Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Fecal Microbiota Transplantation (FMT) Market Size By 2025?
In recent times, there has been a substantial expansion in the size of the fecal microbiota transplantation (FMT) market. The market value is predicted to rise from $0.85 billion in 2024 to $0.91 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. The escalated growth during the historic period is linked to increasing understanding of the gut microbiome, growing scope of therapeutic applications, rise in personalized medicine, and adoption in the field of gastroenterology. Other factors include the increase in clinical trials and a surge in funding and investment activities.

How Big Is the Fecal Microbiota Transplantation (FMT) Market Size Expected to Grow by 2029?
The market size of fecal microbiota transplantation (FMT) is projected to witness robust expansion in the coming years, escalating to $1.19 billion by 2029 with a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period is largely due to escalating cases of clostridium difficile infections (CDI), increasing instances of inflammatory bowel disorders, amplified research and development pursuits, a growing elderly population, and a proliferating healthcare framework. The forecast period is set to see particular trends including the creation of standard procedures for donor evaluation, fecal matter preparation, advancements in microbiome study, enhanced fecal matter processing technologies, innovative delivery techniques, and the creation of artificial or standard microbiota-based products.

View the full report here:
https://www.thebusinessresearchcompany.com/report/fecal-microbiota-transplantation-fmt-global-market-report

Which Key Market Drivers Powering Fecal Microbiota Transplantation (FMT) Market Expansion and Growth?
The escalating incidence of gastrointestinal disorders is anticipated to drive the fecal microbiota transplantation (FMT) market's expansion. Gastrointestinal disorders encompass a broad spectrum of diseases affecting the gut, including the esophagus, stomach, and the entire intestinal tract from the small intestine to the rectum* and anus. This increase in gastrointestinal disorders can be attributed to elevated stress levels, inactive lifestyles, and a rise in the intake of processed food. Fecal microbiota transplantation, which is used to replenish healthy gut bacteria, is especially effective in treating recurrent Clostridioides difficile infections. For example, Crohn's and Colitis Canada, a non-profit organization based in Canada, reported in 2023 that the number of Canadians with IBD is spiking, moving from 322,600 in 2023 (0.8% of the population) to an estimated 470,000 in 2035 (1.1% of the population). Additionally, in 2023, 11,000 individuals will be diagnosed (one every 48 minutes), a number expected to increase to 14,000 (one every 38 minutes) by 2035. Consequently, the increasing occurrences of gastrointestinal disorders are serving as a catalyst for the fecal microbiota transplantation (FMT) market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19430&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Fecal Microbiota Transplantation (FMT) Market?
Leading firms in the Fecal Microbiota Transplantation (FMT) market are directed towards creating pioneering solutions like microbiota-based live biotherapeutics to boost the effectiveness of treatments for gastrointestinal disorders. Microbiota-based live biotherapeutics are essentially living microorganisms utilized as therapeutic substances to repair or modify the gut microbiome to heal different diseases. For instance, Ferring Pharmaceuticals, a biopharmaceutical company based in Switzerland, obtained approval from the United States Food and Drug Administration (FDA) in November 2022 for REBYOTA (fecal microbiota, live-jslm). It's a revolutionary, first-of-its-kind microbiota-based live biotherapeutic developed to prevent relapses of Clostridioides difficile infection (CDI) in people aged 18 and older who have undergone antibiotic treatment for recurring CDI. REBYOTA is specifically engineered to thwart the recurrence of C. difficile infection in individuals aged 18 and over who have been treated with antibiotics for recurrent CDI.

What Are the Emerging Segments in the Fecal Microbiota Transplantation (FMT) Market?
The fecal microbiota transplantation (FMT) market covered in this report is segmented -

1) By Type: Fermentation, Fresh, Cryopreservation
2) By Donor Type: Stool-Derived, Fecal-Derived, Whole-Microbiome Derived
3) By Indication: Clostridioides Difficile Infection, Inflammatory Bowel Disease, Metabolic Syndrome, Other Indications
4) By Administration Route: Oral, Rectal, Nasogastric, Colon Capsule
5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:
1) By Fermentation: Fermented FMT Products, Fermented Capsules, Fermented Liquids, In-House Fermentation Techniques
2) By Fresh: Fresh Stool Samples, Fresh FMT Capsules, Fresh FMT Solutions for In-Hospital Use, Freshly Prepared FMT for Outpatient Use
3) By Cryopreservation: Cryopreserved Stool Samples, Cryopreserved FMT Capsules, Cryopreserved Liquid FMT, Long-Term Storage Solutions for Cryopreserved FMT

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19430&type=smp

Who Are the Global Leaders in the Fecal Microbiota Transplantation (FMT) Market?
Major companies operating in the fecal microbiota transplantation (FMT) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc., Finch Therapeutics Group Inc., Locus Biosciences, Yeda Research and Development Co. Ltd., Microbiotica Limited, CosmosID Inc., AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope

Which are the Top Profitable Regional Markets for the Fecal Microbiota Transplantation (FMT) Industry?
North America was the largest region in the fecal microbiota transplantation (FMT) market in 2024. The regions covered in the fecal microbiota transplantation (FMT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19430

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.